whitepaper
Poster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
List view / Grid view
Targets
whitepaper
Poster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
article
Biomarker identification in the realm of rare diseases
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
news
New findings regarding diabetes risk in childhood cancer survivors
Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.
news
Blastoids enable greater understanding of human gastrulation
Stem-cell based blastocyst models have enabled scientists to redefine the molecular signature and timing of the onset of gastrulation.
news
Eliminating the HIV virus from infected cells with CRISPR-Cas
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
webinar
Neurological disorders: organoids for early drug discovery
14 March 2024 | By Drug Target Review
Join us for this webinar as we explore the role of organoids in advancing treatment of neurological disorders. Organoids, miniature 3D models of human organs, are at the forefront of neuroscience research, offering insights into the complexities of the human brain. In this webinar, esteemed experts will explore the latest…
news
Epstein-Barr virus: new targets for vaccine design and treatment
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
article
Ubiquitous pyrogens and 3D cancer models
A recent study has highlighted the impact of endotoxins on the accuracy of three-dimensional (3D) cancer models. In this Q&A, Dr Bjorn Vergauwen reveals details and key findings of the research.
article
Women in Stem with Leila Jaafar
After gaining her PhD in Biophysics as an International Max-Planck Research School scholar, Leila joined the nuclear field in 2006, starting as an engineer in radiation protection and neutron fluence. Throughout Leila’s career, she has worked across multiple disciplines as a technical project lead in nuclear engineering, lastly in the…
article
The future of cancer immunotherapy with Elicio Therapeutics
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted…
article
Women in Stem with Dr Amber D. Van Laar
Dr Amber Van Laar shares her remarkable journey in STEM. From a childhood fascination with science and medicine to a pivotal role as VP Clinical Development, AskBio. In this interview, she explores the profound impact of her early exposure to neuro-oncology, the challenges faced as a physician-scientist, and the pursuit…
article
Gamma delta T cells: a rising star in cancer therapy
Gamma delta (γδ) T cells comprise a distinct and powerful subpopulation of T cells, bridging innate and adaptive immunity, that holds great promise for treating cancer. IN8Bio co-founder and CEO William Ho and COO Kate Rochlin discuss what makes γδ T cells unique, how preclinical research suggests their antitumour activity…
whitepaper
Beyond the lab: artificial intelligence
Amidst the transformative era of AI in drug discovery, this report focuses on recent advancements, notably the development of highly accurate drug target models, and how AI is revolutionising precision in identifying drug targets.
news
Identification of an immune biomarker for liver cancer
New immunotherapies may be developed for patients with HCC associated with steatotic liver disease, with TREM1 suggested as a target.
